A longitudinal study of more than 10 million active-duty U.S. military personnel has produced some of the strongest evidence yet that Epstein-Barr virus, the pathogen behind infectious mononucleosis, dramatically raises the risk of developing multiple sclerosis. The research, led by Harvard epidemiologist Alberto Ascherio and published in Science in January 2022, found that EBV infection preceded MS onset and increased the likelihood of the disease by roughly 32-fold. That finding, combined with newer mechanistic research showing how the virus tricks the immune system into attacking brain tissue, is reshaping how scientists think about preventing a disease that affects millions worldwide.
A 20-Year Military Cohort Cracked the Case
Multiple sclerosis is a chronic autoimmune disease in which the immune system strips the protective myelin coating from nerve fibers in the brain and spinal cord. For decades, researchers suspected a viral trigger but lacked the data to prove it. The breakthrough came from an unlikely archive, the Department of Defense repository, which stores blood samples collected from service members at regular intervals throughout their careers.
By tracking blood samples drawn every other year from young military personnel over a 20-year span, Ascherio and his team could establish something that cross-sectional studies never could: clear temporal sequence. Soldiers who were initially EBV-negative and later seroconverted showed a 32-fold higher risk of developing MS compared to those who remained uninfected. No other common virus tested in the same cohort produced a comparable signal, which helped rule out the possibility that general immune activation, rather than EBV specifically, was the culprit. A summary from the U.S. National Institutes of Health noted that this work strongly supports the idea that EBV may be causal rather than merely associated.
The scale of the dataset matters. With records from more than 10 million soldiers monitored over two decades, the study had enough statistical power to detect a relationship that smaller trials had only hinted at. Ascherio later received a major international prize for this body of work, a recognition typically reserved for discoveries that shift an entire field and open the door to new kinds of prevention.
Why Mono Carries Extra Danger
EBV is staggeringly common. About 95% of all humans become permanently infected by early adulthood, according to Harvard clinicians. Most people acquire the virus in childhood with few or no symptoms. But when primary infection occurs later, typically in adolescence or young adulthood, it often manifests as infectious mononucleosis, the illness commonly known as mono.
That symptomatic presentation appears to carry additional risk. A meta-analysis of 18 studies involving tens of thousands of cases and controls found a pooled relative risk of approximately 2.17 for MS following a documented bout of mono. In other words, people who experienced the full clinical syndrome of mono were roughly twice as likely to develop MS as those who were infected with EBV silently. Reviews in neurology journals have characterized mono as a higher-risk symptomatic EBV presentation, distinguishing it from the asymptomatic infections that most children experience.
The gap between the 32-fold figure from the military cohort and the roughly two-fold risk from the mono meta-analysis reflects different comparisons. The 32-fold number compares EBV-positive individuals against the small minority who remain EBV-negative, a group in which MS risk is vanishingly low. The 2.17 figure compares mono patients against people who were already EBV-positive but never had symptomatic disease. Both numbers point in the same direction. EBV infection is necessary, and a more intense immune response to it raises the stakes further.
How the Virus Fools the Immune System
Establishing that EBV precedes MS was only half the puzzle. Researchers also needed to explain how a virus that primarily infects B cells in the blood could trigger damage deep inside the brain. Two lines of mechanistic evidence have helped fill that gap.
The first involves molecular mimicry at the antibody level. When the immune system mounts a response against EBNA1, a protein produced by EBV during latent infection, some of the resulting antibodies also bind to GlialCAM, a protein found on cells in the central nervous system. Research published in the Proceedings of the National Academy of Sciences showed that this EBNA1 cross-reactivity was significantly more common in MS patients than in healthy controls. The same work found that MS risk climbed in an additive fashion when these EBV immune markers were combined with the HLA genetic variant DRB1*15:01, the strongest known genetic risk factor for the disease.
The second mechanism operates through T cells rather than antibodies. A study in Cell demonstrated that EBV-specific T cells can also recognize anoctamin-2, a protein expressed in the brain. This means the same immune cells trained to fight EBV can migrate into the central nervous system and attack healthy neural tissue, providing a direct cellular pathway from viral infection to autoimmune brain damage.
Taken together, these findings suggest that EBV does not cause MS through a single mechanism. Instead, both arms of the adaptive immune system can be misdirected. Antibodies that were supposed to target viral proteins instead latch onto myelin-related structures, while T cells activated by EBV acquire the ability to recognize and destroy neurons and glial cells. In genetically susceptible individuals, that misfiring response may become self-sustaining, persisting long after the initial infection has faded into the background.
From Cause to Prevention
Identifying EBV as a necessary cause of MS has immediate implications for prevention strategies. If infection is a prerequisite for disease, then stopping the virus, ideally before adolescence, could, in principle, prevent most cases of MS. That logic has spurred growing interest in EBV vaccines, including candidates that aim to block infection altogether and others designed to blunt the severity of primary illness and reduce the risk of mono.
Even without a licensed vaccine, the new evidence is changing how clinicians talk about risk. People with a history of mono, a strong family history of MS, or high-risk genetic markers may be counseled that they sit at the intersection of multiple risk factors. For them, early recognition of neurological symptoms (such as numbness, visual changes, or balance problems) could enable faster diagnosis and treatment, which is critical because modern MS therapies can substantially slow progression if started early.
The research also underscores the broader lesson that common childhood viruses can have delayed, long-term consequences. Public information services such as MedlinePlus already emphasize the importance of understanding viral infections, immune responses, and chronic disease. As the EBV-MS connection becomes clearer, similar educational efforts may focus more explicitly on how seemingly routine infections can reshape lifelong health trajectories.
What Comes Next
Despite the dramatic advances of the past few years, major questions remain. Not everyone infected with EBV develops MS, which means other factors (genetic background, vitamin D levels, smoking, and additional environmental exposures) still matter. Researchers are now working to map how these elements interact with EBV-driven immune changes to tip some individuals over the threshold into autoimmunity.
At the same time, scientists are exploring whether targeting EBV in people who already have MS could alter the course of the disease. Experimental approaches range from antiviral drugs to engineered immune cells that selectively remove EBV-infected B cells. If such strategies can reduce inflammatory activity in the brain, they would further strengthen the case that EBV is not just an early trigger but an ongoing driver of pathology in at least a subset of patients.
For now, the convergence of large-scale epidemiology and detailed immunology has transformed a long-standing suspicion into a compelling causal story. A ubiquitous virus that most people catch in childhood, and many barely notice, turns out to be a central player in one of neurology’s most feared diagnoses. As work on vaccines and targeted therapies accelerates, the hope is that understanding how EBV sets MS in motion will eventually allow clinicians to stop the disease before it starts, or at least to blunt its impact for the millions already living with it.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
